Glucose transporters in sex steroid hormone related cancer

Current Vascular Pharmacology

Volumn 7, Issue 4, 2009, Pages 534-548

  Nualart, Francisco ^a   García, María de los Angeles ^a   Medina, Rodolfo A ^b   Owen, Gareth I ^c  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Androgen; Breast; Estrogen; Fructose; GLUT; Ovary; Progesterone; Prostate; Testosterone; Uterus

Indexed keywords

2 METHOXYESTRADIOL; ANDROGEN; ASCORBIC ACID; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ERYTHROPOIETIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 10; GLUCOSE TRANSPORTER 11; GLUCOSE TRANSPORTER 12; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 6; GLUCOSE TRANSPORTER 7; GLUCOSE TRANSPORTER 8; GLUCOSE TRANSPORTER 9; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE; TAMOXIFEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; HEART PROTECTION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEMINOMA; TESTIS CANCER; TESTIS CARCINOMA; UTERUS CANCER; UTERUS MYOMA;

ANIMALS; BREAST NEOPLASMS; ESTROGENS; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GONADAL STEROID HORMONES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 70349694075     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109789043928     Document Type: Review

References (190)

1. Fan J, Chaturvedi V, Shen SH. Identification and phylogenetic analysis of a glucose transporter gene family from the human pathogenic yeast Candida albicans. J Mol Evol 2002; 55: 336-46.
2. Weber A, Servaites JC, Geiger DR, Kofler H, Hille D, Groner F, et al. Identification, purification, and molecular cloning of a putative plastidic glucose translocator. Plant Cell 2000; 12: 787-802.
3. Abramson J, Smirnova I, Kasho V, Verner G, Iwata S, Kaback HR. The lactose permease of Escherichia coli: overall structure, the sugar-binding site and the alternating access model for transport. FEBS Lett 2003; 555: 96-101.
4. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 2001; 18: 247-56.
5. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24: 68-72.
6. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
7. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22: 190-274.
8. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987; 235: 1495-8.
9. Medina RA, Southworth R, Fuller W, Garlick PB. Lactate-induced translocation of GLUT1 and GLUT4 is not mediated by the phosphatidyl-inositol-3-kinase pathway in the rat heart. Basic Res Cardiol 2002; 97: 168-76.
10. James DE, Piper RC, Slot JW. Insulin stimulation of GLUT-4 translocation: a model for regulated recycling. Trends Cell Biol 1994; 4: 120-6.
11. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994; 219: 713-25.
12. Stephens JM, Pilch PF. The metabolic regulation and vesicular transport of GLUT4, the major insulin-responsive glucose transporter. Endocr Rev 1995; 16: 529-46.
13. Jung CY. Proteins that interact with facilitative glucose transporters: implication for function. Exp Physiol 1998; 83: 267-73.
14. Lachaal M, Rampal AL, Lee W, Shi Y, Jung CY. GLUT1 transmembrane glucose pathway. Affinity labeling with a transportable D-glucose diazirine. J Biol Chem 1996; 271: 5225-30.
15. Zheng Z, Maidji E, Tugizov S, Pereira L. Mutations in the carboxyl-terminal hydrophobic sequence of human cytomegalovirus glycoprotein B alter transport and protein chaperone binding. J Virol 1996; 70: 8029-40.
16. Asano T, Katagiri H, Takata K, Lin JL, Ishihara H, Inukai K, et al. The role of N-glycosylation of GLUT1 for glucose transport activity. J Biol Chem 1991; 266: 24632-6.
17. Bell ME, Bhatnagar S, Liang J, Soriano L, Nagy TR, Dallman MF. Voluntary sucrose ingestion, like corticosterone replacement, prevents the metabolic deficits of adrenalectomy. J Neuroendocrinol 2000; 12: 461-70.
18. Angulo C, Rauch MC, Droppelmann A, Reyes AM, Slebe JC, Delgado-Lopez F, et al. Hexose transporter expression and function in mammalian spermatozoa: cellular localization and transport of hexoses and vitamin C. J Cell Biochem 1998; 71: 189-203.
19. Godoy A, Ulloa V, Rodriguez F, Reinicke K, Yanez AJ, Garcia Mde L, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006; 207: 614-27.
20. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, et al. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol 2006; 19: 1429-36.
21. von Wolff M, Ursel S, Hahn U, Steldinger R, Strowitzki T. Glucose transporter proteins (GLUT) in human endometrium: expression, regulation, and function throughout the menstrual cycle and in early pregnancy. J Clin Endocrinol Metab 2003; 88: 3885-92.
22. Brown RS, Wahl RL. Over expression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72: 2979-85.
23. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995; 15: 2895-8.
24. Ravazoula P, Batistatou A, Aletra C, Ladopoulos J, Kourounis G, Tzigounis B. Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol 2003; 24: 544-6.
25. Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer 2003; 97: 2035-42.
26. Zimmerman RL, Goonewardene S, Fogt F. Glucose transporter Glut-1 is of limited value for detecting breast carcinoma in serous effusions. Mod Pathol 2001; 14: 748-51.
27. Rudlowski C, Moser M, Becker AJ, Rath W, Buttner R, Schroder W, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 2004; 66: 404-10.
28. Tsukioka M, Matsumoto Y, Noriyuki M, Yoshida C, Nobeyama H, Yoshida H, et al. Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep 2007; 18: 361-7.
29. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Immunohistochemical detection of Glut3 in human tumors and normal tissues. Anticancer Res 1997; 17: 2747-50.
30. Mioni R, Chiarelli S, Xamin N, Zuliani L, Granzotto M, Mozzanega B, et al. Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J Clin Endocrinol Metab 2004; 89: 4089-96.
31. Chan KK, Chan JY, Chung KK, Fung KP. Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5. J Cell Biochem 2004; 93: 1134-42.
32. Burant CF, Bell GI. Mammalian facilitative glucose transporters: evidence for similar substrate recognition sites in functionally monomeric proteins. Biochemistry 1992; 31: 10414-20.
33. Zamora-Leon SP, Golde DW, Concha, II, Rivas CI, Delgado-Lopez F, Baselga J, et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci USA 1996; 93: 1847-52.
34. Li Q, Manolescu A, Ritzel M, Yao S, Slugoski M, Young JD, et al. Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am J Physiol Gastrointest Liver Physiol 2004; 287: G236-42.
35. Doege H, Schurmann A, Bahrenberg G, Brauers A, Joost HG. GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity. J Biol Chem 2000; 275: 16275-80.
36. Schurmann A, Axer H, Scheepers A, Doege H, Joost HG. The glucose transport facilitator GLUT8 is predominantly associated with the acrosomal region of mature spermatozoa. Cell Tissue Res 2002; 307: 237-42.
37. Dawson PA, Mychaleckyj JC, Fossey SC, Mihic SJ, Craddock AL, Bowden DW. Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1. Mol Genet Metab 2001; 74: 186-99.
38. Rogers S, Macheda ML, Docherty SE, Carty MD, Henderson MA, Soeller WC, et al. Identification of a novel glucose transporter-like protein-GLUT-12. Am J Physiol Endocrinol Metab 2002; 282: E733-8.
39. Rogers S, Docherty SE, Slavin JL, Henderson MA, Best JD. Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett 2003; 193: 225-33.
40. Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, Vannucci SJ. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab 2008; 295: E242-53.
41. Garcia MA, Millan C, Balmaceda-Aguilera C, Castro T, Pastor P, Montecinos H, et al. Hypothalamic ependymal-glial cells express the glucose transporter GLUT2, a protein involved in glucose sensing. J Neurochem 2003; 86: 709-24.
42. Doege H, Bocianski A, Joost HG, Schurmann A. Activity and genomic organization of human glucose transporter 9 (GLUT9), a novel member of the family of sugar-transport facilitators predominantly expressed in brain and leucocytes. Biochem J 2000; 350 Pt 3: 771-6.
43. Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 2002; 282: E974-6.
44. Carayannopoulos MO, Chi MM, Cui Y, Pingsterhaus JM, McKnight RA, Mueckler M, et al. GLUT8 is a glucose transporter responsible for insulin-stimulated glucose uptake in the blastocyst. Proc Natl Acad Sci USA 2000; 97: 7313-8.
45. Ibberson M, Uldry M, Thorens B. GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues. J Biol Chem 2000; 275: 4607-12.
46. Kim ST, Moley KH. The expression of GLUT8, GLUT9a, and GLUT9b in the mouse testis and sperm. Reprod Sci 2007; 14: 445-55.
47. Gomez O, Romero A, Terrado J, Mesonero JE. Differential expression of glucose transporter GLUT8 during mouse spermatogenesis. Reproduction 2006; 131: 63-70.
48. McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004; 490: 13-24.
49. Reagan LP, Rosell DR, Alves SE, Hoskin EK, McCall AL, Charron MJ, et al. GLUT8 glucose transporter is localized to excitatory and inhibitory neurons in the rat hippocampus. Brain Res 2002; 932: 129-34.
50. Piroli GG, Grillo CA, Hoskin EK, Znamensky V, Katz EB, Milner TA, et al. Peripheral glucose administration stimulates the translocation of GLUT8 glucose transporter to the endoplasmic reticulum in the rat hippocampus. J Comp Neurol 2002; 452: 103-14.
51. Shin B, McKnight R, SU D. Glucose transporter GLUT8 translocation in neurons is not insulin responsive. J Neurosci Res 2004; 75: 835-44.
52. Widmer M, Uldry M, Thorens B. GLUT8 subcellular localization and absence of translocation to the plasma membrane in PC12 cells and hippocampal neurons. Endocrinology 2005; 146: 4727-36.
53. Gorovits N, Cui L, Busik JV, Ranalletta M, Hauguel de-Mouzon S, Charron MJ. Regulation of hepatic GLUT8 expression in normal and diabetic models. Endocrinology 2003; 144: 1703-11.
54. Lisinski I, Schurmann A, Joost HG, Cushman SW, Al-Hasani H. Targeting of GLUT6 (formerly GLUT9) and GLUT8 in rat adipose cells. Biochem J 2001; 358: 517-22.
55. Zhao F, Miller P, Wall E, Zheng Y, Dong B, Neville M, et al. Bovine glucose transporter GLUT8: cloning, expression, and developmental regulation in mammary gland. Biochim Biophys Acta 2004; 1680: 103-13.
56. Membrez M, Hummler E, Beermann F, Haefliger JA, Savioz R, Pedrazzini T, et al. GLUT8 is dispensable for embryonic development but influences hippocampal neurogenesis and heart function. Mol Cell Biol 2006; 26: 4268-76.
57. Schmidt S, Gawlik V, Holter SM, Augustin R, Scheepers A, Behrens M, et al. Deletion of glucose transporter GLUT8 in mice increases locomotor activity. Behav Genet 2008; 38: 396-406.
58. Gawlik V, Schmidt S, Scheepers A, Wennemuth G, Augustin R, Aumuller G, et al. Targeted disruption of Slc2a8 (GLUT8) reduces motility and mitochondrial potential of spermatozoa. Mol Membr Biol 2008; 25: 224-35.
59. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004; 279: 16229-36.
60. Shikhman AR, Brinson DC, Valbracht J, Lotz MK. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol 2001; 167: 7001-8.
61. Mobasheri A, Neama G, Bell S, Richardson S, Carter SD. Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. Cell Biol Int 2002; 26: 297-300.
62. Mobasheri A, Dobson H, Mason SL, Cullingham F, Shakibaei M, Moley JF, et al. Expression of the GLUT1 and GLUT9 facilitative glucose transporters in embryonic chondroblasts and mature chondrocytes in ovine articular cartilage. Cell Biol Int 2005; 29: 249-60.
63. Carayannopoulos MO, Schlein A, Wyman A, Chi M, Keembiyehetty C, Moley KH. GLUT9 is differentially expressed and targeted in the preimplantation embryo. Endocrinology 2004; 145: 1435-43.
64. McVie-Wylie AJ, Lamson DR, Chen YT. Molecular cloning of a novel member of the GLUT family of transporters, SLC2a10 (GLUT10), localized on chromosome 20q13.1: a candidate gene for NIDDM susceptibility. Genomics 2001; 72: 113-7.
65. Andersen G, Rose CS, Hamid YH, Drivsholm T, Borch-Johnsen K, Hansen T, et al. Genetic variation of the GLUT10 glucose transporter (SLC2A10) and relationships to type 2 diabetes and intermediary traits. Diabetes 2003; 52: 2445-8.
66. Rose CS, Andersen G, Hamid YH, Glumer C, Drivsholm T, Borch-Johnsen K, et al. Studies of relationships between the GLUT10 Ala206Thr polymorphism and impaired insulin secretion. Diabet Med 2005; 22: 946-9.
67. Mohlke KL, Skol AD, Scott LJ, Valle TT, Bergman RN, Tuomilehto J, et al. Evaluation of SLC2A10 (GLUT10) as a candidate gene for type 2 diabetes and related traits in Finns. Mol Genet Metab 2005; 85: 323-7.
68. Bento JL, Bowden DW, Mychaleckyj JC, Hirakawa S, Rich SS, Freedman BI, et al. Genetic analysis of the GLUT10 glucose transporter (SLC2A10) polymorphisms in Caucasian American type 2 diabetes. BMC Med Genet 2005; 6: 42.
69. Lin WH, Chuang LM, Chen CH, Yeh JI, Hsieh PS, Cheng CH, et al. Association study of genetic polymorphisms of SLC2A10 gene and type 2 diabetes in the Taiwanese population. Diabetologia 2006; 49: 1214-21.
70. Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet 2006; 38: 452-7.
71. Drera B, Guala A, Zoppi N, Gardella R, Franceschini P, Barlati S, et al. Two novel SLC2A10/GLUT10 mutations in a patient with arterial tortuosity syndrome. Am J Med Genet A 2007; 143: 216-8.
72. Callewaert BL, Loeys BL, Casteleyn C, Willaert A, Dewint P, De Backer J, et al. Absence of arterial phenotype in mice with homozygous slc2A10 missense substitutions. Genesis 2008; 46: 385-9.
73. Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 2004; 14: 806-12.
74. Gaster M, Handberg A, Schurmann A, Joost HG, Beck-Nielsen H, Schroder HD. GLUT11, but not GLUT8 or GLUT12, is expressed in human skeletal muscle in a fibre type-specific pattern. Pflugers Arch 2004; 448: 105-13.
75. Scheepers A, Schmidt S, Manolescu A, Cheeseman CI, Bell A, Zahn C, et al. Characterization of the human SLC2A11 (GLUT11) gene: alternative promoter usage, function, expression, and subcellular distribution of three isoforms, and lack of mouse orthologue. Mol Membr Biol 2005; 22: 339-51.
76. Gude NM, Stevenson JL, Rogers S, Best JD, Kalionis B, Huisman MA, et al. GLUT12 expression in human placenta in first trimester and term. Placenta 2003; 24: 566-70.
77. Seki Y, Berggren JR, Houmard JA, Charron MJ. Glucose transporter expression in skeletal muscle of endurance-trained individuals. Med Sci Sports Exerc 2006; 38: 1088-92.
78. Stuart CA, Yin D, Howell ME, Dykes RJ, Laffan JJ, Ferrando AA. Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle. Am J Physiol Endocrinol Metab 2006; 291: E1067-73.
79. Zhou Y, Kaye PL, Pantaleon M. Identification of the facilitative glucose transporter 12 gene Glut12 in mouse preimplantation embryos. Gene Expr Patterns 2004; 4: 621-31.
80. Gude NM, Stevenson JL, Murthi P, Rogers S, Best JD, Kalionis B, et al. Expression of GLUT12 in the fetal membranes of the human placenta. Placenta 2005; 26: 67-72.
81. Linden KC, DeHaan CL, Zhang Y, Glowacka S, Cox AJ, Kelly DJ, et al. Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F205-13.
82. Wilson-O'Brien AL, Dehaan CL, Rogers S. Mitogen-stimulated and rapamycin-sensitive glucose transporter 12 targeting and functional glucose transport in renal epithelial cells. Endocrinology 2008; 149: 917-24.
83. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 1999; 59: 4555-8.
84. Nualart F, Godoy A, Reinicke K. Expression of the hexose transporters GLUT1 and GLUT2 during the early development of the human brain. Brain Res 1999; 824: 97-104.
85. Spielholz C, Golde DW, Houghton AN, Nualart F, Vera JC. Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. Cancer Res 1997; 57: 2529-37.
86. Vera JC, Rivas CI, Fischbarg J, Golde DW. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 1993; 364: 79-82.
87. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51: 794-8.
88. Nualart FJ, Rivas CI, Montecinos VP, Godoy AS, Guaiquil VH, Golde DW, et al. Recycling of vitamin C by a bystander effect. J Biol Chem 2003; 278: 10128-33.
89. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
90. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet 2005; 365: 1543-51.
91. Welch RD, Gorski J. Regulation of glucose transporters by estradiol in the immature rat uterus. Endocrinology 1999; 140: 3602-8.
92. Kol S, Ben-Shlomo I, Ruutiainen K, Ando M, Davies-Hill TM, Rohan RM, et al. The midcycle increase in ovarian glucose uptake is associated with enhanced expression of glucose transporter 3. Possible role for interleukin-1, a putative intermediary in the ovulatory process. J Clin Invest 1997; 99: 2274-83.
93. Yamaguchi M, Sakata M, Ogura K, Miyake A. Gestational changes of glucose transporter gene expression in the mouse placenta and decidua. J Endocrinol Invest 1996; 19: 567-9.
94. Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med 2005; 129: 651-4.
95. Chen Y, Nagpal ML, Lin T. Expression and regulation of glucose transporter 8 in rat Leydig cells. J Endocrinol 2003; 179: 63-72.
96. Wu X, Freeze HH. GLUT14, a duplicon of GLUT3, is specifically expressed in testis as alternative splice forms. Genomics 2002; 80: 553-7.
97. Korgun ET, Demir R, Hammer A, Dohr G, Desoye G, Skofitsch G, et al. Glucose transporter expression in rat embryo and uterus during decidualization, implantation, and early postimplantation. Biol Reprod 2001; 65: 1364-70.
98. Zhou J, Bievre M, Bondy CA. Reduced GLUT1 expression in Igf1-/- null oocytes and follicles. Growth Horm IGF Res 2000; 10: 111-7.
99. Medina RA, Meneses AM, Vera JC, Guzman C, Nualart F, Astuya A, et al. Estrogen and progesterone up-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. Endocrinology 2003; 144: 4527-35.
100. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004; 109: 926-32.
101. Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol 1999; 12: 1001-9.
102. Medina RA, Meneses AM, Vera JC, Guzman C, Nualart F, Rodriguez F, et al. Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J Endocrinol 2004; 182: 467-78.
103. Sato M, Nakamura Y, Sogawa T, Yang Q, Taniguchi T, Taniguchi E, et al. Immunolocalization of glucose transporter 1 and 3 in the placenta: application to cytodiagnosis of Papanicolaou smear. Diagn Cytopathol 2002; 26: 373-9.
104. Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 2002; 93: 1123-8.
105. Alo PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, et al. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 2001; 116: 129-34.
106. Stackhouse BL, Williams H, Berry P, Russell G, Thompson P, Winter JL, et al. Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat 2005; 93: 247-53.
107. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 1998; 4: 115-20.
108. Suganuma N, Segade F, Matsuzu K, Bowden DW. Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU Int 2007; 99: 1143-9.
109. Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42: 9-16.
110. Li J, Wang XM, Wang Q, Yang M, Feng XC, Shen ZH. Down-regulation of N-acetylglucosaminyltransferase-V induces ER stress by changing glycosylation and function of GLUT1. Arch Biochem Biophys 2007; 463: 102-9.
111. Sakyo T, Naraba H, Teraoka H, Kitagawa T. The intrinsic structure of glucose transporter isoforms GLUT1 and GLUT3 regulates their differential distribution to detergent-resistant membrane domains in nonpolarized mammalian cells. FEBS J 2007; 274: 2843-53.
112. Godoy A, Salazar K, Figueroa C, Smith G, Garcia M, Nualart F. Nutritional channels in breast cancer. J Cell Mol Med 2008; submitted.
113. Hart CD, Flozak AS, Simmons RA. Modulation of glucose transport in fetal rat lung: a sexual dimorphism. Am J Respir Cell Mol Biol 1998; 19: 63-70.
114. Hsu JT, Kan WH, Hsieh YC, Choudhry MA, Schwacha MG, Bland KI, et al. Mechanism of estrogen-mediated improvement in cardiac function after trauma-hemorrhage: p38-dependent normalization of cardiac Akt phosphorylation and glycogen levels. Shock 2008; 30: 372-8.
115. Alonso A, Gonzalez C. Relationship between non-genomic actions of estrogens and insulin resistace. Infect Disord Drug Targets 2008; 8: 48-51.
116. Shadoan MK, Zhang L, Wagner JD. Effects of hormone therapy on insulin signaling proteins in skeletal muscle of cynomolgus monkeys. Steroids 2004; 69: 313-8.
117. Campbell SE, Angus DJ, Febbraio MA. Glucose kinetics and exercise performance during phases of the menstrual cycle: effect of glucose ingestion. Am J Physiol Endocrinol Metab 2001; 281: E817-25.
118. Campbell SE, Febbraio MA. Effect of the ovarian hormones on GLUT4 expression and contraction-stimulated glucose uptake. Am J Physiol Endocrinol Metab 2002; 282: E1139-46.
119. Sato K, Iemitsu M, Aizawa K, Ajisaka R. Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. Am J Physiol Endocrinol Metab 2008; 294: E961-8.
120. Barros RP, Machado UF, Warner M, Gustafsson JA. Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci USA 2006; 103: 1605-8.
121. Alonso A, Moreno M, Ordonez P, Fernandez R, Perez C, Diaz F, et al. Chronic estradiol treatment improves brain homeostasis during aging in female rats. Endocrinology 2008; 149: 57-72.
122. Shi J, Zhang YQ, Simpkins JW. Effects of 17beta-estradiol on glucose transporter 1 expression and endothelial cell survival following focal ischemia in the rats. Exp Brain Res 1997; 117: 200-6.
123. Cheng CM, Cohen M, Wang J, Bondy CA. Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. FASEB J 2001; 15: 907-15.
124. Keller JN, Germeyer A, Begley JG, Mattson MP. 17Beta-estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid beta-peptide and iron. J Neurosci Res 1997; 50: 522-30.
125. Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menon VP, Bagchi D, et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/AKT/eNOS signaling pathway in diabetic myocardium. J Cell Mol Med 2008; 12(6A): 2350-61.
126. Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 2008; 294: H859-66.
127. Afzal I, Cunningham P, Naftalin RJ. Interactions of ATP, oestradiol, genistein and the anti-oestrogens, faslodex (ICI 182780) and tamoxifen, with the human erythrocyte glucose transporter, GLUT1. Biochem J 2002; 365: 707-19.
128. Vera JC, Reyes AM, Carcamo JG, Velasquez FV, Rivas CI, Zhang RH, et al. Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. J Biol Chem 1996; 271: 8719-24.
129. Vera JC, Reyes AM, Velasquez FV, Rivas CI, Zhang RH, Strobel P, et al. Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochemistry 2001; 40: 777-90.
130. Dip R, Lenz S, Antignac JP, Le Bizec B, Gmuender H, Naegeli H. Global gene expression profiles induced by phytoestrogens in human breast cancer cells. Endocr Relat Cancer 2008; 15: 161-73.
131. Matsumura K, Tanaka T, Kawashima H, Nakatani T. Involvement of the estrogen receptor beta in genistein-induced expression of p21(waf1/cip1) in PC-3 prostate cancer cells. Anticancer Res 2008; 28: 709-14.
132. Penza M, Montani C, Romani A, Vignolini P, Pampaloni B, Tanini A, et al. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology 2006; 147: 5740-51.
133. Verheus M, van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters PH. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007; 25: 648-55.
134. Yearley EJ, Zhurova EA, Zhurov VV, Pinkerton AA. Binding of genistein to the estrogen receptor based on an experimental electron density study. J Am Chem Soc 2007; 129: 15013-21.
135. Meneses AM, Medina RA, Kato S, Pinto M, Jaque MP, Lizama I, et al. Regulation of GLUT3 and glucose uptake by the cAMP signalling pathway in the breast cancer cell line ZR-75. J Cell Physiol 2008; 214: 110-6.
136. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002; 62: 1966-70.
137. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654-62.
138. Douard V, Ferraris RP. Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab 2008; 295: E227-37.
139. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996; 56: 1164-7.
140. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-30.
141. Corpe CP, Bovelander FJ, Munoz CM, Hoekstra JH, Simpson IA, Kwon O, et al. Cloning and functional characterization of the mouse fructose transporter, GLUT5. Biochim Biophys Acta 2002; 1576: 191-7.
142. Levi J, Cheng Z, Gheysens O, Patel M, Chan CT, Wang Y, et al. Fluorescent fructose derivatives for imaging breast cancer cells. Bioconjug Chem 2007; 18: 628-34.
143. Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
144. Wang Y, Iyer M, Annala AJ, Chappell S, Mauro V, Gambhir SS. Noninvasive monitoring of target gene expression by imaging reporter gene expression in living animals using improved bicistronic vectors. J Nucl Med 2005; 46: 667-74.
145. Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell 1997; 89: 9-12.
146. Wang J, Basu HS, Hu L, Feuerstein BG, Nederlof PM, Deen DF. Radiation-induced changes in nucleoid halo diameters of aerobic and hypoxic SF-126 human brain tumor cells. Cytometry 1995; 19: 107-11.
147. Chun YS, Adusumilli PS, Fong Y. Employing tumor hypoxia for oncolytic therapy in breast cancer. J Mammary Gland Biol Neoplasia 2005; 10: 311-8.
148. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006; 13: 739-49.
149. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007; 67: 3441-9.
150. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006; 3: e47.
151. Ahrens WA, Ridenour RV 3rd, Caron BL, Miller DV, Folpe AL. GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol 2008; 39: 1519-26.
152. Glasker S, Tran MG, Shively SB, Ikejiri B, Lonser RR, Maxwell PH, et al. Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. J Pathol 2006; 210: 32-41.
153. Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, Yoshie M, et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res 2006; 66: 11263-70.
154. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 2007; 97: 646-53.
155. Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 1999; 14: 105-10.
156. Wheeler MD, Ikejema K, Enomoto N, Stacklewitz RF, Seabra V, Zhong Z, et al. Glycine: a new anti-inflammatory immunonutrient. Cell Mol Life Sci 1999; 56: 843-56.
157. Young A. Inhibition of glucagon secretion. Adv Pharmacol 2005; 52: 151-71.
158. Shetty M, Ismail-Beigi N, Loeb JN, Ismail-Beigi F. Induction of GLUT1 mRNA in response to inhibition of oxidative phosphorylation. Am J Physiol 1993; 265: C1224-9.
159. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003; 162: 1283-91.
160. Kallinowski F, Tyler G, Mueller-Klieser W, Vaupel P. Growth-related changes of oxygen consumption rates of tumor cells grown in vitro and in vivo. J Cell Physiol 1989; 138: 183-91.
161. Richard C, Charreau B, Vusio P, Soulillou JP, Bouhours JF. Characterization of two monoclonal antibodies against porcine VCAM-1. Hybridoma 1999; 18: 159-65.
162. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-9.
163. Semenza GL. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin North Am 1994; 8: 863-84.
164. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
165. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev 1998; 17: 187-94.
166. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 22642-7.
167. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008; 15: 621-7.
168. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-85.
169. Li BZ, Zhuang WZ, Chen P, Fu JX. [Effects of RNA interference targeting hypoxia-inducible factor-1alpha (HIF-1alpha) on chemosensitivity of leukemia K562 cells towards homoharringtonine]. Ai Zheng 2008; 27: 723-8.
170. Ozbudak IH, Karaveli S, Simsek T, Erdogan G, Pestereli E. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol 2008; 108: 603-8.
171. Currie MJ, Hanrahan V, Gunningham SP, Morrin HR, Frampton C, Han C, et al. Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol 2004; 57: 829-34.
172. Iida T, Yasuda M, Miyazawa M, Fujita M, Osamura RY, Hirasawa T, et al. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression. Arch Gynecol Obstet 2008; 277: 539-46.
173. Mabjeesh NJ, Shefler A, Amir S, Matzkin H. Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells. Prostate 2008; 68: 679-89.
174. Cho J, Bahn JJ, Park M, Ahn W, Lee YJ. Hypoxic activation of unoccupied estrogen-receptor-alpha is mediated by hypoxiainducible factor-1 alpha. J Steroid Biochem Mol Biol 2006; 100: 18-23.
175. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 6394-9.
176. Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, et al. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res 2008; 68: 1872-80.
177. Jiang LX, Xu J, Wang ZW, Li DP, Peng ZH, Gao JJ, et al. Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma. World J Gastroenterol 2008; 14: 5606-11.
178. Kapitsinou PP, Haase VH. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 2008; 15: 650-9.
179. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446: 444-8.
180. Hanze J, Weissmann N, Grimminger F, Seeger W, Rose F. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 2007; 97: 774-87.
181. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26: 281-90.
182. Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, Ellenson LH, et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/-mice. Cancer Res 2006; 66: 3375-80.
183. Begum M, Tashiro H, Katabuchi H, Suzuki A, Kurman RJ, Okamura H. Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice. Lab Invest 2006; 86: 286-96.
184. Ao A, Wang H, Kamarajugadda S, Lu J. Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors. Proc Natl Acad Sci USA 2008; 105: 7821-6.
185. Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A, et al. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008; 172: 534-44.
186. Maraldi T, Prata C, Fiorentini D, Zambonin L, Landi L, Hakim G. Signal processes and ROS production in glucose transport regulation by thrombopoietin and granulocyte macrophage-colony stimulation factor in a human leukaemic cell line. Free Radic Res 2007; 41: 1348-57.
187. Kanda N, Watanabe S. 17beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression. J Invest Dermatol 2003; 121: 1500-9.
188. Robertson SA, Mayrhofer G, Seamark RF. Ovarian steroid hormones regulate granulocyte-macrophage colony-stimulating factor synthesis by uterine epithelial cells in the mouse. Biol Reprod 1996; 54: 183-96.
189. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007; 8: 285-92.
190. Subbarayan PR, Wang PG, Lampidis TJ, Ardalan B, Braunschweiger P. Differential expression of GLUT 1 mRNA and protein levels correlates with increased sensitivity to the glyco-conjugated nitric oxide donor (2-glu-SNAP) in different tumor cell types. J Chemother 2008; 20: 106-11.